These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30408164)

  • 1. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
    Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
    Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
    [No Abstract]   [Full Text] [Related]  

  • 2. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
    Mannis G; Wu D; Dea T; Mauro T; Hsu G
    Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
    [No Abstract]   [Full Text] [Related]  

  • 3. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
    Michallet AS; Campidelli A; Lequeu H; Dilhuydy MS; Tournilhac O; Fornecker LM; Dupuis J; Cymbalista F; De Guibert S; Delmer A; Vilque JP; Ghez D; Leblond V; Subtil F; Feugier P; Ysebaert L
    Am J Hematol; 2017 Jun; 92(6):E105-E107. PubMed ID: 28295510
    [No Abstract]   [Full Text] [Related]  

  • 5. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
    Kolomeyer AM; Hwang CK; Kim BJ
    J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
    Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
    Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
    [No Abstract]   [Full Text] [Related]  

  • 8. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
    Mato AR; Islam P; Daniel C; Strelec L; Kaye AH; Brooks S; Ganetsky A; Nasta S; Porter DL; Svoboda J; Nabhan C; Schuster SJ
    Blood; 2016 Feb; 127(8):1064-7. PubMed ID: 26702066
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia.
    Giovanni B; Ibatici A; Sola S; Brunasso AMG; Massone C
    Am J Dermatopathol; 2020 Feb; 42(2):148-150. PubMed ID: 30839345
    [No Abstract]   [Full Text] [Related]  

  • 13. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
    Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
    JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib induced acute tubular injury: A case series and review of the literature.
    Manohar S; Bansal A; Wanchoo R; Sakhiya V; Lucia S; Jhaveri KD
    Am J Hematol; 2019 Sep; 94(9):E223-E225. PubMed ID: 31148235
    [No Abstract]   [Full Text] [Related]  

  • 16. Ibrutinib-Induced Neutrophilic Dermatosis.
    El Halabi L; Cherif-Rebai K; Michot JM; Ghez D
    Am J Dermatopathol; 2018 Mar; 40(3):198-200. PubMed ID: 29473834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib-associated oral ulcers.
    Thermos G; Tosios KI
    Oral Oncol; 2020 Jan; 100():104445. PubMed ID: 31629661
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
    Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
    [No Abstract]   [Full Text] [Related]  

  • 19. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
    Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Jones JA; Hillmen P; Coutre S; Tam C; Furman RR; Barr PM; Schuster SJ; Kipps TJ; Flinn IW; Jaeger U; Burger JA; Cheng M; Ninomoto J; James DF; Byrd JC; O'Brien SM
    Br J Haematol; 2017 Jul; 178(2):286-291. PubMed ID: 28397242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.